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Vascular endothelial growth factor (VEGF) is probably the single
angiogenic inducer that contributes the most to the angiogenesis of
human tumours (Kim et al, 1993; Pötgens et al, 1995; Claffey et al,
1996). Basic fibroblast growth factor (bFGF) might promote
tumour angiogenesis by interacting with VEGF (Goto et al, 1993;
Seghezzi et al, 1998). VEGF is up-regulated when cells are
exposed to hypoxia in vitro and nearby necrosis in vivo (Shweiki
et al, 1992; Hlatky et al, 1994). Other more direct studies have also
suggested that induction of VEGF by hypoxia is an important
signal for tumour angiogenesis. Shweiki et al (1995) have demon-
strated up-regulation of VEGF in the centrally located, hypoxic
cells of spheroids grown in vitro, which was followed by vascular-
ization and VEGF down-regulation when the spheroids were
transplanted in vivo. Moreover, hypoxia-induced upregulation of
VEGF in human tumour cells in vitro can increase tumour angio-
genesis when the cells are grown as xenografts in vivo (Rofstad
and Danielsen, 1998). The observation that hypoxia stimulates
angiogenesis, together with the fact that VEGF is up-regulated in
normal cells by hypoxia (Shweiki et al, 1992; Hlatky et al, 1994),
suggest tumour angiogenesis to be an inherent physiological
process, i.e. an example of tissue signalling its environment to
provide increased vascularization (D’Amore and Shima, 1996). If
this is the main mechanism of angiogenesis in tumours, one would
expect strong VEGF expression in relatively hypoxic tumours,
while well-oxygenated tumours would show little VEGF expres-
sion. A correlation between high VEGF protein expression and
hypoxia was indeed seen in rectal carcinoma (Mattern et al, 1996).
Although different VEGF levels in tumours can originate as a
result of hypoxia, VEGF secretion and mRNA levels do also differ
significantly between tumour cells of the same histological origin
grown under normoxic conditions in vitro (Westphal et al, 1997;
Rofstad and Danielsen, 1998). Thus, it seems likely that genetic
changes during tumour progression modulate the VEGF expression
of the tumour cells. An increase in VEGF expression can be an
important step in the tumorigenic process, as it promotes angiogen-
esis and thereby tumour growth (D’Amore and Shima, 1996). If the
constitutive, genetically determined level of VEGF is an important
factor in tumour angiogenesis, a high vascular density would be
expected in tumours with a high VEGF expression. A correlation
between high vascular density in vascular ‘hot spots’ of the
tumours and high VEGF expression has been observed in different
histological types of clinical cancer specimens (Guidi et al, 1995;
Takahashi et al, 1995; Obermair et al, 1997). Moreover, transfec-
tion of VEGF into human cancer cells has been shown to increase
the vascular density of tumour xenografts (Claffey et al, 1996).
The angiogenesis of tumours can probably be regulated both by
normal physiological mechanisms and by genetic mechanisms
specific for tumour cells. Thus, Mazure et al (1996) have found
hypoxia and oncogenic transformation to act synergistically in the
modulation of VEGF expression in rodent fibroblasts. However,
the relative importance of hypoxia-induced and genetically deter-
mined VEGF expression in the angiogenesis of human tumours
has not been studied. Therefore, we wanted to investigate the
possibility that VEGF-induced angiogenesis is mediated mainly
by one of these mechanisms in melanomas. Four human
melanoma xenografts (A-07, D-12, R-18 and U-25) that are wild-
type for TP53 were used as a model system, in which VEGF and
bFGF expression in vivo were compared to the hypoxic fraction,
the angiogenic potential and the vascular density.
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MATERIALS AND METHODS
Mice and tumour lines
Adult Balb/c nu/nu mice, bred at our research institute, were used
as host animals for xenografted tumours. The mice were main-
tained under specific pathogen-free conditions at constant temper-
ature (24–26°C) and humidity (30–50%). Sterilized food and tap
water were given ad libitum.
The experiments were performed using four human melanoma
cell lines (A-07, D-12, R-18, U-25) (Rofstad, 1994). Xenografted
tumours were initiated from exponentially growing monolayer
cultures in passages 75–100. Monolayer cells, cultured in RPMI-
1640 medium (25 mM HEPES and L-glutamin) supplemented with
13% fetal bovine serum (FBS), 250 mg l–1 penicillin and 50 mg l–1
streptomycin, were detached by trypsinization (treatment with
0.05% trypsin/0.02% EDTA solution at 37°C for 2 min).
Approximately 3.5 ´ 105 cells in 10 ml of Ca2+- and Mg2+-free
Hanks’ balanced salt solution (HBSS) were inoculated intrader-
mally in the flanks of mice by using a 100 ml Hamilton syringe.
Tumour volume (V) was calculated as V = p/6 ´ ab2, where a is the
longer and b is the shorter of two perpendicular tumour diameters,
measured with calipers. Tumours with volumes within the range of
200–400 mm3 were used for experiments. The growth and histo-
logical appearance of the tumours have been described in detail
previously (Rofstad, 1994).
Immunohistochemical analysis of VEGF and bFGF
expression
Immunohistochemical staining of tumour tissue was performed
using the avidin–biotin immunoperoxidase method. Tumours were
fixed in 4% phosphate-buffered paraformaldehyde and embedded
in paraffin casts (VEGF staining), or dropped into liquid N2 imme-
diately after excision and kept at –80°C until staining (bFGF). The
paraffin sections (5 mm thick) were treated with 0.6% hydrogen
peroxide (H2O2) to block endogenous peroxidase and all sections
were blocked with normal goat serum before incubating with the
primary antibody (30-min incubation). The primary antibodies
were the rabbit polyclonal antibodies VEGF (A-20) used at 5.0
and 10.0 mg ml–1 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and bFGF (147) used at 2.5 mg ml–1 (Santa Cruz
Biotechnology). Controls included omission of primary antibody,
incubation with normal rabbit immunoglobulin or normal rabbit
serum and incubation with blocking peptides against VEGF and
bFGF (Santa Cruz Biotechnology) before staining. The sections
were counterstained with haematoxylin. Optimal antibody concen-
trations were found in preliminary titration experiments. The
immunostaining for VEGF was performed in two batches, staining
two tumours from each tumour line in the first and three tumours
from each tumour line in the second batch. Care was taken in order
to achieve the same experimental conditions for all tumour
sections.
After staining, all sections were studied under light microscope
for evaluation of protein localization (intracellular vs extracel-
lular) and intra-tumour and inter-tumour heterogeneity in protein
expression. In order to compare the VEGF staining of the four
melanoma lines, pictures from the sections (approximately 600 ´
600 mm) were displayed on a monitor. The pictures were recorded
by the image processing system KS300 (Kontron Elektronik,
Munich, Germany), connected to the microscope through a CCD-
camera. Equal light conditions and image processing parameters
were used for all tumour lines. Five tumours of each line and two
pictures of each tumour, preferably from different sections, were
subjected to analysis. The VEGF staining of the pictures was eval-
uated by two slightly different methods. In the first method, four
pictures, one from each melanoma line, were displayed on the
monitor, compared according to staining intensity and ranked.
This procedure was performed for all pictures, and a final ranking
was made based on the total amount of data. In the second method,
each picture was evaluated separately and given a number
according to staining intensity (1, weak staining; 2, intermediate
staining; 3, strong staining). The resulting data from this semi-
quantitative evaluation were thereafter analysed by statistical
methods in order to reveal statistically significant differences in
staining intensity between the tumour lines.
Measurements of metabolic hypoxia
The hypoxia marker pimonidazole was used to measure fraction of
metabolically hypoxic cells, i.e. cells that have sufficiently low
oxygen tension to metabolize and bind pimonidazole (Raleigh et
al, 1998). Pimonidazole is a nitroimidazole, which is selectively
metabolized by hypoxic cells to a form that binds covalently to
cellular macromolecules. The binding of nitroimidazoles shows a
similar dependence on the concentration of oxygen as cellular
radiosensitivity.
Mice were given an intraperitoneal injection of pimonidazole in
doses of 30 mg g–1 body weight approximately 4 h before the mice
were killed. The pimonidazole-marked tumours were excised,
fixed in 4% phosphate-buffered paraformaldehyde and cut into
four parts before embedding in paraffin casts. The sections 
were stained with anti-pimonidazole using the avidin–biotin
immunoperoxidase method. The paraffin sections (5 mm thick)
were treated with 3.0% H2O2 to block endogenous peroxidase,
blocked with normal goat serum and treated with proteinase E
(0.1 mg ml–1) to digest enzymes prior to primary antibody incuba-
tion (overnight incubation). Rabbit polyclonal anti-pimonidazole
was a personal gift from Dr JA Raleigh. Controls included
omission of primary antibody and incubation with normal rabbit
immunoglobulin or normal rabbit serum. The sections were coun-
terstained with haematoxylin. Optimal antibody concentration was
found in preliminary titration experiments.
The fraction of a tumour showing pimonidazole staining was
found by using the image processing system KS300 (Kontron
Elektronik, Munich, Germany). The metabolic hypoxic fraction
was defined as the pimonidazole-stained area fraction of the 
non-necrotic tumour area. The area fraction of each section that
contained non-necrotic tumour tissue was found by subtracting the
necrotic area fraction from the total area. For each melanoma line,
16–25 tumours were analysed, using 2–4 sections from different
parts of each tumour and up to 100 randomly selected fields of
view.
Statistical analysis
Statistical comparisons of data were performed by one-way
analysis of variance (ANOVA) under conditions of normality and
equal variance and otherwise by the Kruskal–Wallis one-way
ANOVA on ranks. Student–Newman–Keul’s test was thereafter
used to identify groups that differed from the others. A signifi-
cance criterion of P < 0.05 and two-sided tests were used. The1530 T Danielsen and EK Rofstad
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statistical analysis was performed using Sigmastat statistical soft-
ware (Jandel, Erkrath, Germany).
RESULTS
Immunohistochemical staining of tumour sections with an anti-
body specific for VEGF revealed VEGF expression in all tumours
of all four melanoma lines. The positive staining seemed to be
localized mainly in the cytoplasm of the cells (Figure 1, A–D).
Within a tumour, the staining was relatively homogenous, and only
a very few negative cells were observed. VEGF was slightly up-
regulated nearby necrosis in some areas of the tumours (Figure 2).
This up-regulation was most clearly seen in the U-25 line, where
cells adjacent to necrotic areas often showed slightly higher VEGF
expression than other cells (Figure 2B). The D-12 line also showed
up-regulation of VEGF close to necrosis, however, stronger
staining was only seen in some of the cells, and cells with high
VEGF expression were distributed over a larger distance away
from the necrotic area than what was seen in U-25 (Figure 2A).
The two lines A-07 and R-18 showed little or no necrosis.
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Figure 1 Immunohistochemical preparations of the human melanoma xenografts A-07 (A and E), D-12 (B and F), R-18 (C and G) and U-25 (D and H).
Paraformaldehyde-fixed sections were stained with anti-VEGF (A–D)(5 mg ml–1), and frozen sections were stained with anti-bFGF (E–H) (2.5 mg ml–1), using the
avidin–biotin immunoperoxidase method. All sections were counterstained with haematoxylin. bFGF staining around a blood vessel is shown in panel E
(arrowhead). Scale bars, 100 mm
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Figure 2 Immunohistochemical preparations of the human melanoma xenografts D-12 (A) and U-25 (B). Paraformaldehyde-fixed sections were stained with
anti-VEGF (10 mg ml–1) by the avidin–biotin immunoperoxidase method and counterstained with haematoxylin. Scale bars, 100 mm and 20 mm (high
magnifications); n, necrosisVEGF/bFGF in angiogenesis of melanoma xenografts 1531
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The VEGF staining was found to be substantially stronger for
A-07 than for the other three lines when groups of four pictures
were compared (i.e. A-07 was ranked number one in almost all
groups). Moreover, the staining of D-12 was slightly stronger than
that of R-18 and U-25 by this method (i.e. D-12 was ranked
number two more often than either R-18 or U-25). Significantly
higher VEGF staining of A-07 than of the other three lines was
also detected when pictures were evaluated separately (P < 0.05).
No differences in staining intensities between D-12, R-18 and 
U-25 were detected by this method (P > 0.05). The staining was
performed in two batches. No differences in the evaluation results
were found when the two groups were evaluated separately.
Positive bFGF staining was seen in all four tumour lines by
immunohistochemical staining (Figure 1, E–H). The staining of A-
07 was mainly localized in intensively stained areas intracellularly.
Weaker staining of areas close to blood vessels and extracellularly
was also seen in A-07 (Figure 1E). The other three lines showed
weaker intracellular staining than A-07, but the staining nearby
blood vessels and extracellularly was comparable to that of A-07
(Figure 1, F–H). The bFGF expression of individual tumours was
quite homogenous for all the lines, and no negative areas were
observed.
Pimonidazole staining of tumour sections was assessed to deter-
mine the fraction of metabolically hypoxic cells in the tumour
lines. Tumour sections showing positive pimonidazole staining are
shown in Figure 3. The well-defined stained areas were seen as
blotches in tumour tissue without significant necrosis (Figure 3A),
or adjacent to large necrotic areas (Figure 3B). Pimonidazole
staining was not directly associated with VEGF staining, as it was
seen in certain areas of the tumours only, while VEGF staining
was observed all over the tumours, except for some necrotic areas.
Pimonidazole staining was not directly associated with VEGF up-
regulation either, as it was often detected in areas without necrosis,
whereas VEGF up-regulation was only seen close to necrotic
areas. Moreover, pimonidazole staining was seen adjacent to all
necrotic areas, while VEGF was slightly up-regulated close to
some of the necrotic areas only.
The fraction of metabolically hypoxic cells was significantly
lower for A-07 than for the three other lines (P < 0.05) (Figure
4A). R-18 showed a significantly lower fraction of metabolically
hypoxic cells than D-12 and U-25 (P < 0.05). The fraction of
metabolically hypoxic cells did not differ significantly between
D-12 and U-25 (P > 0.05).
By comparing the fraction of metabolically hypoxic cells to data
published previously (Rofstad and Måseide, 1998) on the fraction
of radiobiologically hypoxic cells (Figure 4B), both similarities
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Figure 3 Immunohistochemical preparations of the human melanoma
xenografts R-18 (A) and U-25 (B) stained with anti-pimonidazole using the
avidin–biotin immunoperoxidase method and counterstained with
haematoxylin. Scale bars, 100 mm; n, necrosis; arrowheads, blood vessels
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Figure 4 Hypoxic fractions of the human melanoma xenografts A-07, D-12,
R-18 and U-25. (A) Metabolic hypoxic fractions obtained by staining tumour
sections with the hypoxia marker pimonidazole and measuring the stained
area fraction of the non-necrotic tissue. Columns and bars represent the
mean ± s.e.m. of 16–25 tumours. (B) Radiobiological hypoxic fractions
obtained by the local tumour control assay (Rofstad and Måseide, 1998)1532 T Danielsen and EK Rofstad
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and discrepancies between the assays were observed. A-07
showed a significantly lower fraction both of metabolically
hypoxic cells and of radiobiologically hypoxic cells than the other
three lines (P < 0.05). On the other hand, the significant difference
between R-18 and U-25 in fraction of metabolically hypoxic cells
was not detected when the fraction of radiobiologically hypoxic
cells was measured. Moreover, D-12 showed a significantly lower
fraction of radiobiologically hypoxic cells than R-18 and U-25 
(P < 0.05).
Previously published data on the angiogenic potential of the
melanoma cells (Danielsen and Rofstad, 1998) and the vascular
density of melanoma xenografts (Tufto et al, 1998) are summa-
rized in Table 1. A-07 showed significantly higher angiogenic
potential and vascular density than the other three lines (P < 0.05).
Whereas significant differences in angiogenic potential were seen
between all cell lines (P < 0.05), there were no significant differ-
ences in the vascular density of the lines D-12, R-18 and U-25
(P > 0.05).
DISCUSSION
Four human melanoma lines showing differential expression of
angiogenic inducers in vitro (Danielsen and Rofstad, 1998) were
used as tumour models in the present study. When assessing the
expression of angiogenic inducers in vivo, it is important to use a
tumour model in which the expression is not partly originating
from host cells. Several normal cell types have been shown to
express VEGF and bFGF at normoxic conditions and to up-regu-
late VEGF expression at hypoxic conditions (Cordon-Cardo et al,
1990; Shweiki et al, 1992; Hlatky et al, 1994). However, as host
cells (macrophages, leucocytes, fibroblasts) constitute less than
1% of the total number of cells in the xenografted melanomas
(Rofstad, 1994), VEGF and bFGF detected in vivo are most likely
of human origin. Furthermore, both VEGF and bFGF seemed to be
localized mainly intracellularly by immunohistochemistry, and
both inducers were detected by Western blotting of the melanoma
cells grown in vitro (Danielsen and Rofstad, 1998). Accordingly,
the model system used here was suitable for in vivo investigation
of VEGF and bFGF expression.
VEGF expression was found to be considerably higher in the 
A-07 line than in the three other lines, both by direct comparison
of pictures from the four tumour lines and by semi-quantitative
analysis of tumour sections. The high VEGF expression of A-07
might partly be a result of bFGF stimulation, since A-07 also
showed substantially higher intracellular bFGF expression in vivo
than the other melanoma lines. Our present results are in agree-
ment with in vitro data on the melanoma cells, showing the A-07
cell line to secrete significantly more VEGF and to express consid-
erably more bFGF than the other three cell lines, and to be the only
cell line secreting detectable amounts of bFGF (Danielsen and
Rofstad, 1998).
Angiogenic potential, measured as number of tumour-oriented
capillaries, and mean vascular density were significantly higher
for A-07 than for the other three lines. Thus, our data suggest an
association between VEGF/bFGF expression in vivo and angio-
genesis, indicating that VEGF and possibly bFGF are important
for the angiogenesis of the melanoma xenografts. The significance
of VEGF in the angiogenesis of the melanoma xenografts is under-
scored by experiments in which mice injected with melanoma cells
were treated with anti-VEGF neutralizing antibody, resulting in
significant decrease in the angiogenic potential (Rofstad and
Danielsen, 1999).
Measurements of the fraction of metabolically hypoxic cells
showed that the hypoxic fraction of A-07 was significantly lower
than that of D-12, R-18 and U-25. As different assays of tumour
hypoxia measure different parameters, the numerical values of the
hypoxic fractions of tumours can be assay-dependent. However,
results from the radiobiological assay also indicated that the
hypoxic fraction of A-07 was lower than that of D-12, R-18 and
U-25. Moreover, as vascular density is related to the oxygenation
status of a tumour (Mattern et al, 1996; Lyng et al, 1997), the
significantly higher vascular density of A-07 than of the other lines
is consistent with the results achieved by determining hypoxic
fraction. Measurements of the oxygenation status of the melanoma
xenografts by the Eppendorf pO2 histograph also resulted in a
higher oxygenation status for A-07 than for the other three lines
(H Lyng, unpublished results). Taken together, these data strongly
suggest that the hypoxic fraction of A-07 is significantly lower
than that of D-12, R-18 and U-25.
Our data did not reveal any relationship between high VEGF
expression and high hypoxic fraction. On the contrary, high VEGF
expression was related to low hypoxic fraction and high vascular
density, suggesting a negative correlation between VEGF expres-
sion and hypoxic fraction in the melanoma xenografts. Since a
positive correlation between VEGF expression and hypoxic frac-
tion would be expected if the VEGF-induced angiogenesis of the
melanomas was mainly mediated through hypoxia, we suggest the
angiogenesis of the melanoma xenografts to be driven mainly by
other factors than hypoxia-induced VEGF. This conclusion is
supported by the lack of co-localization between VEGF staining
and staining for the hypoxia marker pimonidazole, an observation
that has also been reported for clinical specimens (Raleigh et al,
1998). Our conclusion is not in line with the recent suggestion that
the mRNA expression of VEGF may be used as a marker for
radiobiologic hypoxia (Chiarotto and Hill, 1999).
Specific, genetic properties of the tumour cells are probably
decisive of the VEGF expression and thereby the angiogenesis of
the melanomas studied here. This conclusion is supported by
several observations. Firstly, contrary to the results of Pötgens et al
(1995), our data show the pattern of VEGF and bFGF expression to
be similar whether the melanoma cells are grown as xenografts in
vivo or as monolayer cultures under normoxic conditions in vitro
(Danielsen and Rofstad, 1998). The growth conditions in vitro were
equal for all cell lines, and differences in VEGF/bFGF expression
between the lines should therefore represent genetic differences.
Secondly, as the VEGF/bFGF expression of the melanoma lines in
vivo is related to the vascular density, it is likely that the constitu-
tive, genetically determined level of VEGF is decisive for the
Table 1 Angiogenic potential and vascular density of human melanoma
xenografts
Melanoma Angiogenic potentiala Vascular densityb
A-07 151 ± 10 48 ± 4
D-12 64 ± 8 22 ± 2
R-18 48 ± 6 20 ± 2
U-25 39 ± 5 21 ± 4
aNumber of tumour-oriented capillaries at day 7 after intradermal inoculation of
3.5 ´ 105 melanoma cells; mean ± s.e. (Danielsen and Rofstad, 1998).
bVessels/area of non-necrotic tissue (no./mm2); mean ± s.e. (Tufto et al, 1998). angiogenesis and thus the hypoxic fraction of the melanoma lines,
and not the other way round, that hypoxia is decisive for the VEGF
level. Thus, the angiogenesis of the melanoma xenografts is prob-
ably driven mainly by genetic mechanisms, and to a less extent by
hypoxia-induced VEGF. Our results are in accordance with data
from Westphal et al (1997), showing high VEGF expression and
high mean vascular density to be associated in a study of seven
human tumour xenografts. Moreover, the present study is consis-
tent with the view that tumour angiogenesis is a result of both
normal physiological processes and genetic properties of the
tumour cells (D’Amore and Shima, 1996; Mazure et al, 1996).
When searching for genetic properties important for differences
in VEGF expression, TP53 status is a possible candidate as cells
transiently transfected with mutant TP53 show higher VEGF
expression than cells transiently transfected with wild-type TP53
(Mukhopadhyay et al, 1995). Moreover, expression of VEGF and
mutant TP53, measured by immunohistochemistry, were related in
lung cancer (Fontanini et al, 1995) and in colon cancer (Takahashi
et al, 1998). The four melanoma lines used in this study do all
express wild-type TP53 (Danielsen et al, 1999). Thus, the
observed difference in VEGF expression between A-07 and the
other three lines must be attributed to genetic properties other than
TP53 status.
To summarize, our data suggest that hypoxia is not decisive for
VEGF expression and thus angiogenesis of melanomas. The
constitutive, genetically determined level of VEGF is probably
more important than the hypoxia-induced VEGF in the angio-
genesis of this type of tumours. This conclusion is drawn in a
tumour model system in which the TP53 status of all lines is equal,
i.e. wild-type TP53.
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